NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination study
Nes Ziona, Israel (ots/PRNewswire) - Intradermal COVID-19 vaccination studies are emerging in a global effort to use available doses more effectively by harnessing skin immunity to reduce the dosage required for effective vaccination, as well as to improve the immunogenicity of weaker vaccines. Additionally, there is a pressing global need to improve the durability of COVID-19 vaccines universally.
With a view to specifically improving the cell mediated immune response, Emergex has initiated a Phase I clinical study!-->…